

### Turning Point Brands Announces Fourth Quarter and Full Year 2023 Results

-Net Sales for Q4 2023 Zig-Zag and Stoker's Products Increased 5.9 Percent Year-Over-Year -Adjusted EBITDA for Q4 2023 of \$24.8 Million Increased 7.5 Percent Year-Over-Year -FY 2023 Free Cash Flow of \$61.2 Million

**LOUISVILLE, KY – February 28, 2024 –** Turning Point Brands, Inc. ("TPB" or "the Company") (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, announced today financial results for the fourth quarter and full year ended December 31, 2023.

### Q4 2023 vs. Q4 2022

- Total consolidated net sales decreased 6.1% to \$97.1 million
  - O Zig-Zag Products net sales decreased by 2.9%
  - O Stoker's Products net sales increased by 18.6%
  - Creative Distribution Solutions net sales decreased by 43.7%
- Gross profit increased 1.9% to \$50.5 million
- Net income increased \$26.4 million to \$10.1 million
- Adjusted net income increased 15.9% to \$15.3 million (see Schedule B for a reconciliation to net income)
- Adjusted EBITDA increased 7.5% to \$24.8 million (see Schedule A for a reconciliation to net income)
- Diluted EPS of \$0.53 and Adjusted Diluted EPS of \$0.79 compared to \$(0.93) and \$0.69 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)

# FY 2023 vs. FY 2022

- Total consolidated net sales decreased 2.3% to \$405.4 million
  - Zig-Zag Products net sales decreased by 5.2%
  - Stoker's Products net sales increased by 10.5%
  - Creative Distribution Solutions net sales decreased by 14.3%
- Gross profit decreased 1.1% to \$203.2 million
- Net income increased 230.4% to \$38.5 million
- Adjusted net income increased 1.1% to \$56.8 million (see Schedule B for a reconciliation to net income)
- Adjusted EBITDA decreased 2.4% to \$95.3 million (see Schedule A for a reconciliation to net income)
- Diluted EPS of \$2.01 and Adjusted Diluted EPS of \$2.91 compared to \$0.64 and \$2.83 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)

Graham Purdy, President and CEO, commented: "Our fourth quarter results were at the high-end of our expectations. The Zig-Zag segment was stable from the previous year excluding the impact of a discontinued product line and is well positioned to return to growth in 2024. Stoker's had an outstanding quarter posting its highest growth rate in over four years led by double-digit growth year-over-year in Stoker's MST. We also had strong free cash flow generation during the year allowing us to build a cash

balance to address the remaining principal amount of our convertible notes at maturity in July. Our outlook for 2024 is positive as we expect solid growth in our Zig-Zag and Stoker's Products businesses."

# Zig-Zag Products Segment (46% of total net sales in the quarter)

For the fourth quarter, Zig-Zag Products net sales decreased 2.9% to \$45.1 million due to the discontinuation of an unprofitable product line in Canada that impacted sales by \$1.4 million.

For the quarter, the Zig-Zag Products segment gross profit decreased 1.0% to \$25.5 million. Gross margin increased 100 basis points to 56.5% driven by product mix.

For the full year, net sales of Zig-Zag Products decreased 5.2% to \$180.5 million due to the reduction of trade inventory earlier in the year and the discontinuation of an unprofitable product line in Canada that impacted sales by \$4.9 million.

For the full year, Zig-Zag Products segment gross profit decreased 5.2% to \$101.1 million. Gross margin was steady at 56.0%.

"Our US Zig-Zag papers and alternative channel business posted a strong quarter with double-digit growth to close the year," said Purdy. "With the reduction of trade inventory through the year, Zig-Zag is now positioned to return to growth aided by industry secular growth trends and internal growth initiatives."

## Stoker's Products Segment (39% of total net sales in the quarter)

For the fourth quarter, Stoker's Products net sales increased 18.6% to \$38.0 million on double-digit growth of MST and high-single-digit growth of loose-leaf. For the fourth quarter, total Stoker's Products segment volume increased 14.2%, while price / mix increased 4.4%.

For the quarter, the Stoker's Products segment gross profit increased 27.2% to \$21.9 million. Gross margin expanded 380 basis points to 57.6% due to MST pricing gains and operating leverage.

For the full year, net sales of Stoker's Products increased 10.5% to \$144.6 million on double-digit growth of MST and low-single-digit growth of loose-leaf. For the full year, total Stoker's Products segment volume increased 4.2%, while price / mix increased 6.3%.

For the full year, the Stoker's Products segment gross profit increased 14.9% to \$81.9 million. Gross margin increased 210 basis points to 56.6% due to MST pricing gains.

"Stoker's had an exceptional quarter with strong market share gains in both the MST and loose-leaf categories as its value proposition continues to resonate with consumers," continued Purdy. "We are excited about the planned expansion of our FRĒ white nicotine pouch product throughout the year."

# **Performance Measures in the Fourth Quarter**

Fourth quarter consolidated selling, general and administrative ("SG&A") expenses were \$30.9 million compared to \$31.2 million in the fourth quarter of 2022.

Fourth quarter SG&A included the following notable items:

- \$1.9 million of stock options, restricted stock and incentive expense compared to \$1.2 million in the year-ago period
- \$1.0 million of FDA PMTA-related expenses for modern oral products compared to \$0.3 million in the year-ago period
- \$0.2 million of restructuring costs compared to \$1.8 million in the year-ago period
- \$0.1 million of ERP / CRM duplicative system costs compared to \$0.3 million of ERP / CRM scoping expenses in the year-ago period

Total gross debt as of December 31, 2023 was \$368.5 million. Net debt (total gross debt less unrestricted cash) at December 31, 2023 was \$250.7 million. The Company ended the quarter with total liquidity of \$177.9 million, comprised of \$117.9 million in cash and \$60.0 million of revolving credit facility capacity.

During the quarter, the Company received a net federal excise tax refund of \$4.3 million, which is included in other operating income and \$0.8 million of interest income related to the refund, which is included in net interest expense. The Company also recorded \$4.0 million in other income related to a legal settlement receivable and a \$1.0 million impairment of a minority investment in a development stage venture.

### 2024 Outlook

Management expects full-year 2024 adjusted EBITDA to be \$95 to \$100 million. This excludes any contribution from our CDS business which contributed a little over \$2 million of EBITDA in FY 2023.

## Creative Distribution Solutions ("CDS") (15% of total net sales in the quarter)

For the fourth quarter, CDS net sales were \$14.1 million, gross profit was \$3.1 million, and gross margin was 22.4%.

# **Earnings Conference Call**

As previously disclosed, a conference call with the investment community to review TPB's financial results has been scheduled for 10:00 a.m. Eastern on Wednesday, February 28, 2024. Investment community participants should dial in 10 minutes ahead of time using the toll-free number 888-330-2502 (international participants should call 240-789-2713), and follow the audio prompts after typing in the event ID: 6640134. A live listen-only webcast of the call will be available on the Events and Presentations section of the investor relations portion of the Company website (<a href="www.turningpointbrands.com">www.turningpointbrands.com</a>). A replay of the webcast will be available on the site two hours following the call.

### **Non-GAAP Financial Measures**

In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, Adjusted Operating Income (Loss) and Free Cash Flow. A reconciliation of these non-GAAP financial measures accompanies this release.

## **About Turning Point Brands, Inc.**

Turning Point Brands (NYSE: TPB) is a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients through its iconic Zig-Zag® and Stoker's® brands. TPB's products are available in more than 215,000 retail outlets in North America, and on sites such as <a href="https://www.zigzag.com">www.zigzag.com</a>. For the latest news and information about TPB and its brands, please visit <a href="https://www.turningpointbrands.com">www.turningpointbrands.com</a>.

## **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the Securities and Exchange Commission (the "SEC") and other public statements made from time-to-time speak only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict or identify all such events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to those included it the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by the Company with the SEC. These statements constitute the Company's cautionary statements under the Private Securities Litigation Reform Act of 1995.

### **Investor Contacts**

Turning Point Brands, Inc.: Louie Reformina, Senior Vice President, CFO Turning Point Brands, Inc. 502.774.9238 ir@tpbi.com

Financial Statements Follow:

## **Consolidated Statements of Income**

(dollars in thousands except share data) (unaudited)

(unununeu)	Three Months En							
		iber 31,						
	2023	2022						
Net sales	\$ 97,120	\$ 103,392						
Cost of sales	46,596	53,829						
Gross profit	50,524	49,563						
Selling, general, and administrative expenses	30,916	31,245						
Other operating income, net	(4,345)	-						
Operating income	23,953	18,318						
Interest expense, net	2,632	4,382						
Investment loss	934	7,229						
Other income	(4,000)	-						
Goodwill and intangible impairment loss	-	27,566						
Loss (gain) on extinguishment of debt	194	(885)						
Income (loss) before income taxes	24,193	(19,974)						
Income tax expense (benefit)	14,328	(3,857)						
Consolidated net income (loss)	9,865	(16,117)						
Net (loss) income attributable to non-controlling interest	(244)	200						
Net income (loss) attributable to Turning Point Brands, Inc.	\$ 10,109	\$ (16,317)						
Basic income (loss) per common share:								
Net income (loss) attributable to Turning Point Brands, Inc.	\$ 0.57	\$ (0.93)						
Diluted income (loss) per common share:								
Net income (loss) attributable to Turning Point Brands, Inc.	\$ 0.53	\$ (0.93)						
Weighted average common shares outstanding:								
Basic	17,604,313	17,530,278						
Diluted	20,153,157	17,530,278						
Supplemental disclosures of statement of income information:								
Excise tax expense	\$ 5,137	\$ 5,771						
FDA fees	\$ 138	\$ 158						

# **Consolidated Statements of Income**

(dollars in thousands except share data) (unaudited)

For the year	r ended
Decembe	r 31.

	Decem	er 31,			
	2023	2022			
Net sales	\$ 405,393	\$ 415,013			
Cost of sales	202,152	209,475			
Gross profit	203,241	205,538			
Selling, general, and administrative expenses	125,009	130,024			
Other operating income, net	(4,345)	-			
Operating income	82,577	75,514			
Interest expense, net	14,645	19,524			
Investment loss	11,914	13,303			
Other income	(4,000)	-			
Goodwill and intangible impairment loss	-	27,566			
Gain on extinguishment of debt	(1,664)	(885)			
Income before income taxes	61,682	16,006			
Income tax expense	23,901	4,849			
Consolidated net income	37,781	11,157			
Net loss attributable to non-controlling interest	(681)	(484)			
Net income attributable to Turning Point Brands, Inc.	\$ 38,462	\$ 11,641			
Basic income per common share:					
Net income attributable to Turning Point Brands, Inc.	\$ 2.19	\$ 0.65			
Diluted income per common share:					
Net income attributable to Turning Point Brands, Inc.	\$ 2.01	\$ 0.64			
Weighted average common shares outstanding:					
Basic	17,578,270	17,899,794			
Diluted	20,467,406	18,055,015			
Supplemental disclosures of statement of income information:					
Excise tax expense	\$ 20,575	\$ 23,274			
FDA fees	\$ 586	\$ 623			

## **Consolidated Balance Sheets**

(dollars in thousands except share data) (unaudited)

Accounts receivable, net of allowances of \$78 in 2023 and \$114 in 2022         9,989         11,911           Other current assets         40,781         22,95           Total current assets         25,765         257,65           Property, plant, and equipment, net         25,300         22,78           Deferred income taxes         1,468         8,44           Right of use assets         1,468         8,44           Right of use assets         2,450         28           Goodwill         316,250         136,250           Other intangible assets, net         80,942         83,59           Other assets         28,684         27,980           Total assets         15,166         25,204           Total assets         8,942         83,55           Accrued liabilities         33,353         33,00           Current portion of long-term debt, net         58,244         -           Other current liabilities         9,950         10,59           Total current liabilities         9,950         10,59	(unauanea)	December 31,						
Cash         \$ 117,886         \$ 106,400           Accounts receivable, net of allowances of \$78 in 2023 and \$114 in 2022         9,9896         119,915           Inventories, net         98,960         119,915           Other current assets         20,7616         227,55           Property, plant, and equipment, net         25,300         22,78           Right of use assets         11,488         12,460           Deferred financing costs, net         28,00         28,00           Goodwill         136,250         136,252           Other intangible assets, net         89,942         88,359           Master Settlement Agreement (MSA) escrow deposits         28,684         27,988           Other sussets         15,166         22,644           Total assets         15,166         22,644           Total counts payable         \$ 8,407         \$ 8,35           Accounts payable         \$ 8,407         \$ 8,35           Accured liabilities         2 9         -           Current portion of long-term debt, net         90,03         40,375           Other current liabilities         9,950         10,30           Total liabilities         9,950         10,30           Total liabilities         9,950	ASSETS		2023		2022			
Accounts receivable, net of allowances of \$78 in 2023 and \$14 in 2022   9,989   13,971   Inventories, net of allowances of \$78 in 2023 and \$14 in 2022   19,915   Other current assets								
Pubmic   P	Cash	\$		\$	106,403			
Other current assers         40,781         22,955           Total current assers         267,616         257,655           Property, plant, and equipment, net         25,300         22,781           Deferred income taxes         11,468         8,444           Right of use assers         11,146         8,444           Right of use assers         11,168         2,850           Odowill         2,450         2,850           Other intangible assets, net         80,942         83,590           Master Settlement Agreement (MSA) escrow deposits         28,684         27,980           Other assets         15,166         22,648           Total assets         5,593,355         35,72,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities         33,635         33,603           Accrued liabilities         33,635         33,003           Current portion of long-term debt, net         5,824         -           Other current liabilities         100,336         41,378           Notes payable and long-term debt         9,95         10,59           Lease liabilities         9,95         10,59           Total liabilities         10,03         41,378      <	Accounts receivable, net of allowances of \$78 in 2023 and \$114 in 2022		9,989		8,377			
Total current assets         267,616         257,65           Property, plant, and equipment, net         25,300         22,780           Deferred income taxes         1,468         8,84           Right of use assets         11,480         12,460           Deferred financing costs, net         2,450         28           Goodwill         136,250         136,250           Other intangible assets, net         80,942         83,59           Master Settlement Agreement (MSA) escrow deposits         28,684         27,980           Other assets         15,166         22,644           Total assets         \$ 8,097         \$ 8,359           Accounts payable         \$ 8,407         \$ 8,359           Accured liabilities         33,635         33,00           Current portion of long-term debt, net         58,294         -           Other current liabilities         - 20         20           Total current liabilities         - 9,950         10,336           Total current liabilities         - 9,950         10,959           Total current liabilities         - 9,950         10,959           Total current liabilities         - 9,950         10,959           Total current liabilities         - 9,950         10,9	Inventories, net		98,960		119,915			
Property, plant, and equipment, net         25,300         22,780           Deferred income taxes         1,468         8,44           Right of use assets         11,460         12,460           Deferred financing costs, net         2,450         28           Goodwill         3136,252         136,252           Other intangible assets, net         80,942         83,592           Master Settlement Agreement (MSA) escrow deposits         28,684         27,980           Other assets         15,166         22,644           Total assets         \$569,356         \$572,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities         33,635         33,00           Accounts payable         \$8,407         \$8,355           Accounts payable         \$8,407         \$8,355           Account payable         \$8,407         \$8,235           Account payable         \$8,407	Other current assets		40,781		22,959			
Deferred income taxes         1,468         8,44.           Right of use assets         11,480         12,460           Deferred financing costs, net         2,28           Goodwill         136,250         136,252           Other intangible assets, net         80,942         83,59           Master Settlement Agreement (MSA) escrow deposits         28,684         77,980           Other assets         15,166         22,64           Total assets         \$ 569,356         \$ 572,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities         \$ 8,407         \$ 8,355           Accounts payable         \$ 8,407         \$ 8,355           Accured liabilities         33,635         33,00           Current protion of long-term debt, net         5 8,294         -           Other current liabilities         100,336         41,37           Notes payable and long-term debt         307,064         406,755           Lease liabilities         9,950         10,599           Total current liabilities         100,336         413,78           Commitments and contingencies         2         -           Stockholders'equity:         -         - <td colspan<="" td=""><td>Total current assets</td><td></td><td>267,616</td><td></td><td>257,654</td></td>	<td>Total current assets</td> <td></td> <td>267,616</td> <td></td> <td>257,654</td>	Total current assets		267,616		257,654		
Right of use assets         11,480         12,460           Deferred financing costs, net         2,450         28           Goodwill         136,252         136,252           Other intangible assets, net         80,942         83,595           Master Settlement Agreement (MSA) escrow deposits         28,684         27,986           Other assets         15,166         22,644           Total assets         569,356         \$ 572,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities:           Accrued liabilities         33,635         33,00           Current portion of long-term debt, net         58,294            Other current liabilities         303,035         41,37           Notes payable and long-term debt         100,336         41,37           Notes payable and long-term debt         99,50         10,59           Total liabilities         99,50         10,59           Total liabilities         99,50         10,59           Total liabilities         10         447,37           Commitments and contingencies           Stockholders' equity:           Preferred stock: \$0.01 par value; authorized shares 40,00	Property, plant, and equipment, net		25,300		22,788			
Deferred financing costs, net         2,450         28,50           Goodwill         136,250         136,250           Other intangible assets, net         80,942         83,59,20           Master Settlement Agreement (MSA) escrow deposits         28,684         27,980           Other assets         15,166         22,648           Total assets         559,356         \$ 572,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities         8,8407         \$ 8,355           Accued liabilities         33,635         33,00           Current portion of long-term debt, net         58,294            Other current liabilities          20           Total current liabilities          20           Notes payable and long-term debt         30,70,64         406,755           Lease liabilities         9,950         10,532           Total current liabilities         9,950         10,532           Total liabilities         9,950         10,532           Commitments and contingencies             Commitments and contingencies           Stockholders' equity:        <	Deferred income taxes		1,468		8,443			
Goodwill         136,250         136,250           Other intangible assets, net         80,942         83,593           Master Settlement Agreement (MSA) escrow deposits         22,648         72,988           Other assets         15,166         22,648           Total assets         5,693,350         \$72,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities         8,8407         \$8,355           Accounts payable         \$8,407         \$8,355           Accrued liabilities         33,635         33,000           Current portion of long-term debt, net         58,294         -           Other current liabilities         -         2           Total current liabilities         30,005         41,375           Notes payable and long-term debt         30,006         406,75           Lease liabilities         9,950         10,593           Total liabilities         9,950         10,593           Total liabilities         1,005,607         417,350         458,724           Commitments and contingencies         5         -         -         -         -         -         -         -         -         -         -         -         -         - <td>Right of use assets</td> <td></td> <td>11,480</td> <td></td> <td>12,465</td>	Right of use assets		11,480		12,465			
Other intangible assets, net         80,942         83,592           Master Settlement Agreement (MSA) escrow deposits         22,868         27,968           Other assets         15,166         22,280           Total assets         569,356         \$ 572,100           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities         \$ 8,407         \$ 8,355           Accounts payable         \$ 8,407         \$ 8,355           Accrued liabilities         33,635         33,000           Current portion of long-term debt, net         58,294         -           Other current liabilities         -         2           Total current liabilities         300,064         406,75           Lease liabilities         300,064         406,75           Lease liabilities         9,950         10,592           Total liabilities         9,950         10,592           Commitments and contingencies         2         -           Stockholders' equity:         -         -           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0         -         -           Common stock, voring, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued share, 17,485,163         199         196 <td>Deferred financing costs, net</td> <td></td> <td>2,450</td> <td></td> <td>282</td>	Deferred financing costs, net		2,450		282			
Master Settlement Agreement (MSA) escrow deposits         28,684         27,986           Other assets         15,166         22,648           Total assets         569,356         \$ 572,106           LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities           Accounts payable         \$ 8,407         \$ 8,355           Accrued liabilities         33,635         33,000           Current portion of long-term debt, net         \$ 8,294         -           Other current liabilities         100,336         41,376           Otter current liabilities         100,336         41,376           Notes payable and long-term debt         307,064         406,75           Lease liabilities         9,950         10,592           Total liabilities         41,335         458,722           Commitments and contingencies         ***         ***           Stockholders' equity:         ***         ***         ***           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares, 17,005,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163         199         198           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares at December 31, 2022         ***         ***	Goodwill		136,250		136,253			
Total assets	Other intangible assets, net		80,942		83,592			
Total assets   Se9,356   Se72,100	Master Settlement Agreement (MSA) escrow deposits		28,684		27,980			
LIABILITIES AND STOCKHOLDERS' EQUITY           Current liabilities:           Accrued liabilities         33,635         33,000           Current portion of long-term debt, net         58,294         -           Other current liabilities         100,336         41,376           Notes payable and long-term debt         307,064         406,757           Lease liabilities         9,950         10,592           Total liabilities         9,950         10,592           Commitments and contingencies         417,350         458,720           Stockholders' equity:         -         -         -           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         -         -         -           Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,485,163         199         196           outstanding shares at December 31, 2022         199         196         19           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued shares, 17,485,163         199         196         19           Cost of repurchased common stock         (7,80,901)         (78,093)         (78,093)         (78,093)         (78,093)         (78,093)         (78,093)         (78,093)         (78,093) <td>Other assets</td> <td></td> <td>15,166</td> <td></td> <td>22,649</td>	Other assets		15,166		22,649			
Current liabilities:   Sador   Sador	Total assets	\$	569,356	\$	572,106			
Accounts payable         \$ 8,407         \$ 8,355           Accrued liabilities         33,635         33,000           Current portion of long-term debt, net         58,294         -           Other current liabilities         -         20           Total current liabilities         100,336         41,376           Notes payable and long-term debt         307,064         406,75           Lease liabilities         9,950         10,592           Total liabilities         417,350         458,726           Commitments and contingencies         -         -         -           Stockholders' equity:         -         -         -         -           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         -         -         -           Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,485,163         199         198           outstanding shares at December 31, 2022         199         199         198           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; 19,922,137 issued shares, 119,007         199         199         199           Cost of repurchased common stock         (2,316,460 shares at December 31, 2023 and 2022)         (78,093)         (78,093)         (78,093)	LIABILITIES AND STOCKHOLDERS' EQUITY							
Accrued liabilities         33,635         33,000           Current portion of long-term debt, net         58,294         -           Other current liabilities         -         20           Total current liabilities         307,064         406,755           Notes payable and long-term debt         307,064         406,755           Lease liabilities         9,950         10,595           Total liabilities         9,950         10,595           Commitments and contingencies           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         - <td>Current liabilities:</td> <td></td> <td></td> <td></td> <td></td>	Current liabilities:							
Current portion of long-term debt, net         58,294         -           Other current liabilities         -         20           Total current liabilities         100,336         41,376           Notes payable and long-term debt         307,064         406,757           Lease liabilities         9,950         10,592           Total liabilities         9,950         10,592           Commitments and contingencies         -         -           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         -         -           Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163         199         199           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares at December 31, 2022         199         199           Additional paid-in capital         119,075         113,242           Cost of repurchased common stock         (2,316,460 shares at December 31, 2023 and 2022)         (78,093)         (78,093)           Accumulated other comprehensive loss         (2,648)         (2,393)           Accumulated earnings         112,443         78,691           Non-controlling interest <td>Accounts payable</td> <td>\$</td> <td>8,407</td> <td>\$</td> <td>8,355</td>	Accounts payable	\$	8,407	\$	8,355			
Other current liabilities         -         20           Total current liabilities         100,336         41,376           Notes payable and long-term debt         307,064         406,75           Lease liabilities         9,950         10,595           Total liabilities         417,350         458,720           Commitments and contingencies           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         -         -           Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163         199         198           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares at December 31, 2022         199         198           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-         -         -           Additional paid-in capital         119,075         113,242           Cost of repurchased common stock         (78,093)         (78,093)           Accumulated other comprehensive loss         (78,093)         (78,093)           Accumulated other comprehensive loss         (2,648)         (2,394)           Non-controlling interest	Accrued liabilities		33,635		33,001			
Total current liabilities         100,336         41,376           Notes payable and long-term debt         307,064         406,757           Lease liabilities         9,950         10,592           Total liabilities         417,350         458,726           Commitments and contingencies           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         -         -           Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163         199         198           outstanding shares at December 31, 2022         199         198           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares at December 31, 2023         199         198           Additional paid-in capital         119,075         113,242           Cost of repurchased common stock         (2,316,460 shares at December 31, 2023 and 2022)         (78,093)         (78,093)           Accumulated other comprehensive loss         (2,648)         (2,393)           Accumulated earnings         11,2443         78,699           Non-controlling interest         1,030         1,733           Total stockholders' equity	Current portion of long-term debt, net		58,294		-			
Notes payable and long-term debt         307,064         406,757           Lease liabilities         9,950         10,592           Total liabilities         417,350         458,726           Commitments and contingencies           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         -         -           Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163         199         198           outstanding shares at December 31, 2022         199         199         198           Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-         -         -         -           Additional paid-in capital         119,075         113,242         -           Cost of repurchased common stock         (2,316,460 shares at December 31, 2023 and 2022)         (78,093)         (78,093)           Accumulated other comprehensive loss         (2,648)         (2,393)           Accumulated earnings         112,443         78,695           Non-controlling interest         1,030         1,733           Total stockholders' equity         152,006         113,386	Other current liabilities		-		20			
Lease liabilities         9,950         10,593           Total liabilities         417,350         458,726           Commitments and contingencies           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         - <td>Total current liabilities</td> <td></td> <td>100,336</td> <td></td> <td>41,376</td>	Total current liabilities		100,336		41,376			
Lease liabilities         9,950         10,593           Total liabilities         417,350         458,726           Commitments and contingencies           Stockholders' equity:           Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-         - <td>Notes payable and long-term debt</td> <td></td> <td>307,064</td> <td></td> <td>406,757</td>	Notes payable and long-term debt		307,064		406,757			
Total liabilities         417,350         458,726           Commitments and contingencies         Stockholders' equity:         -					10,593			
Stockholders' equity:         Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-       -       -       -         Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares,       17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163       199       198         common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000;       -       -       -         issued and outstanding shares -0-       -       -       -         Additional paid-in capital       119,075       113,242         Cost of repurchased common stock       (2,316,460 shares at December 31, 2023 and 2022)       (78,093)       (78,093)         Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	Total liabilities				458,726			
Preferred stock; \$0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-       -       -       -         Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163 outstanding shares at December 31, 2022       199       198         Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-       -       -       -         Additional paid-in capital       119,075       113,242         Cost of repurchased common stock       (2,316,460 shares at December 31, 2023 and 2022)       (78,093)       (78,093)         Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	Commitments and contingencies							
Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023, and 19,801,623 issued shares, 17,485,163 outstanding shares at December 31, 2022       199       198         Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-       -       -       -         Additional paid-in capital       119,075       113,242       119,075       113,242         Cost of repurchased common stock       (2,316,460 shares at December 31, 2023 and 2022)       (78,093)       (78,093)       (78,093)         Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	* ·							
outstanding shares at December 31, 2022       199       198         Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-       -       -         Additional paid-in capital       119,075       113,242         Cost of repurchased common stock       (78,093)       (78,093)         4ccumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	Common stock, voting, \$0.01 par value; authorized shares, 190,000,000; 19,922,137 issued shares,		-		-			
Additional paid-in capital       119,075       113,242         Cost of repurchased common stock       (2,316,460 shares at December 31, 2023 and 2022)       (78,093)       (78,093)         Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	outstanding shares at December 31, 2022 Common stock, nonvoting, \$0.01 par value; authorized shares, 10,000,000;		199		198			
Cost of repurchased common stock       (78,093)       (78,093)         (2,316,460 shares at December 31, 2023 and 2022)       (78,093)       (78,093)         Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	e e e e e e e e e e e e e e e e e e e		-		-			
(2,316,460 shares at December 31, 2023 and 2022)       (78,093)       (78,093)         Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,693         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	1 1		119,075		113,242			
Accumulated other comprehensive loss       (2,648)       (2,393)         Accumulated earnings       112,443       78,691         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	Cost of repurchased common stock							
Accumulated earnings       112,443       78,69         Non-controlling interest       1,030       1,733         Total stockholders' equity       152,006       113,380	(2,316,460 shares at December 31, 2023 and 2022)		(78,093)		(78,093)			
Non-controlling interest         1,030         1,735           Total stockholders' equity         152,006         113,380	Accumulated other comprehensive loss		(2,648)		(2,393)			
Total stockholders' equity 152,006 113,380	Accumulated earnings		112,443		78,691			
Total stockholders' equity 152,006 113,380	Non-controlling interest		1,030		1,735			
Total liabilities and stockholders' equity \$ 569.356 \$ 572.100			152,006		113,380			
	Total liabilities and stockholders' equity	\$	569,356	\$	572,106			

# **Turning Point Brands, Inc. Consolidated Statements of Cash Flows**

(dollars in thousands) (unaudited)

	December 31,								
		2023	,	2022					
Cash flows from operating activities:									
Consolidated net income	\$	37,781	\$	11,157					
Adjustments to reconcile net income to net cash provided by operating activities:									
Gain on extinguishment of debt		(1,664)		(885)					
Loss (gain) on sale of property, plant, and equipment		90		(9)					
Loss on goodwill impairment		-		25,585					
Loss on intangible asset impairment		-		1,982					
Gain on insurance recovery of inventory loss		(15,181)		-					
Loss on investments		12,177		13,570					
Depreciation and other amortization expense		3,262		3,388					
Amortization of other intangible assets		3,096		1,911					
Amortization of deferred financing costs		2,445		2,576					
Deferred income tax expense (benefit)		7,024		(6,506)					
Stock compensation expense		6,561		5,273					
Noncash lease income		(82)		(29)					
Gain on MSA escrow deposits		-		(54)					
Changes in operating assets and liabilities:									
Accounts receivable		(1,609)		(2,103)					
Inventories		20,977		(32,653)					
Other current assets		(3,533)		4,581					
Other assets		(4,835)		420					
Accounts payable		(14)		1,240					
Accrued liabilities and other		386		830					
Net cash provided by operating activities		66,881		30,273					
Cash flows from investing activities:									
Capital expenditures	\$	(5,707)	\$	(7,685)					
Payments for investments		(202)		(1,000)					
Restricted cash, MSA escrow deposits		-		(10,170)					
Proceeds on the sale of property, plant and equipment		3_		62					
Net cash used in investing activities		(5,906)		(18,793)					

For the Year Ended

# Turning Point Brands, Inc. Consolidated Statements of Cash Flows (Cont.)

(dollars in thousands) (unaudited)

# For the Year Ended December 31,

December 51,									
	2023		2022						
	(41,794)		(9,000)						
	114		51						
	(4,497)		(4,250)						
	(2,437)		-						
	450		504						
	(346)		(155)						
	(995)		(1,229)						
	-		(29,224)						
\$	(49,505)	\$	(43,303)						
\$	11,470	\$	(31,823)						
\$	13	\$	(320)						
\$	106,403	\$	128,320						
	4,929		15,155						
\$	111,332	\$	143,475						
\$	117.886	\$	106,403						
Ψ	*	+	4,929						
\$	122,815	\$	111,332						
	\$ \$ \$	\$ 106,403 \$ 117,886 \$ 4,929	\$\begin{array}{cccccccccccccccccccccccccccccccccccc						

## **Non-GAAP Financial Measures**

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, Adjusted Gross Profit and Adjusted Operating Income (Loss). We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, Adjusted Gross Profit and Adjusted Operating Income (Loss) are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors. We believe that EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, Adjusted Gross Profit and Adjusted Operating Income (Loss) are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.

We define "EBITDA" as net income (loss) before interest expense, gain (loss) on extinguishment of debt, provision for (benefit from) income taxes, depreciation and amortization. We define "Adjusted EBITDA" as net income before interest expense, gain (loss) on extinguishment of debt, provision for (benefit from) income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Net Income" as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Diluted EPS" as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Gross Profit: as gross profit excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Operating Income (Loss)" as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Free Cash Flow" as "Net Cash provided by operating activities" less Capital expenditures.

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. EBITDA, Adjusted Net Income, Adjusted EBITDA Adjusted Diluted EPS, Adjusted Gross Profit and Adjusted Operating Income (Loss) exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and are subject to inherent limitations. In addition, other companies in our industry may calculate these non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting their usefulness as comparative measures.

In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.

#### Schedule A

# **Turning Point Brands, Inc.**

### Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA

(dollars in thousands) (unaudited)

	Three Mor Decem			
	2023	2022		
Net income (loss) attributable to Turning Point Brands, Inc.	\$ 10,109	\$ (16,317)		
Add:				
Interest expense, net	2,632	4,382		
Loss (gain) on extinguishment of debt	194	(885)		
Income tax expense (benefit)	14,328	(3,857)		
Depreciation expense	804	777		
Amortization expense	851	538		
EBITDA	\$ 28,918	\$ (15,362)		
Components of Adjusted EBITDA	<del></del>			
Corporate and CDS restructuring (a)	199	1,825		
ERP/CRM (b)	138	336		
Stock options, restricted stock, and incentives expense (c)	1,901	1,170		
Transactional expenses and strategic initiatives(d)	3	12		
FDA PMTA (e)	1,003	289		
Non-cash asset impairment (f)	1,015	34,836		
FET refund (g)	(4,345)	-		
Legal settlement (h)	(4,000)	-		
Adjusted EBITDA	\$ 24,832	\$ 23,106		

<sup>(</sup>a) Represents costs associated with corporate and CDS restructuring, including severance.

<sup>(</sup>b) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.

<sup>(</sup>c) Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.

<sup>(</sup>d) Represents the fees incurred for transaction expenses.

<sup>(</sup>e) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").

<sup>(</sup>f) Represents impairment of goodwill, intangible and investment assets.

<sup>(</sup>g) Represents federal excise tax refund included in other operating income, net.

<sup>(</sup>h) Represents other income from litigation settlement.

### Schedule A

## **Turning Point Brands, Inc.**

# Reconciliation of GAAP Net Income to Adjusted EBITDA

(dollars in thousands) (unaudited)

	For the Ye Decemb	
	2023	2022
Net income attributable to Turning Point Brands, Inc.	\$ 38,462	\$ 11,641
Add:		
Interest expense, net	14,645	19,524
Gain on extinguishment of debt	(1,664)	(885)
Income tax expense	23,901	4,849
Depreciation expense	3,121	3,388
Amortization expense	3,237	1,911
EBITDA	\$ 81,702	\$ 40,428
Components of Adjusted EBITDA		
Corporate and CDS restructuring (a)	389	3,444
ERP/CRM (b)	552	1,962
Stock options, restricted stock, and incentives expense (c)	6,561	5,273
Transactional expenses and strategic initiatives (d)	165	801
FDA PMTA (e)	2,098	4,554
Non-cash asset impairment (f)	12,177	41,136
FET refund (g)	(4,345)	-
Legal settlement (h)	(4,000)	-
Adjusted EBITDA	\$ 95,299	\$ 97,598

<sup>(</sup>a) Represents costs associated with corporate and CDS restructuring, including severance.

<sup>(</sup>b) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.

 $<sup>(</sup>c) \ \ Represents \ non-cash \ stock \ options, \ restricted \ stock, \ incentives \ expense \ and \ Solace \ performance \ stock \ units.$ 

<sup>(</sup>d) Represents the fees incurred for transaction expenses.

 $<sup>(</sup>e) \ \ Represents \ costs \ associated \ with \ applications \ related \ to \ FDA \ premarket \ to bacco \ product \ application \ ("PMTA").$ 

 $<sup>(</sup>f) \ \ Represents \ impairment \ of \ goodwill, intangible \ and \ investment \ assets.$ 

<sup>(</sup>g) Represents federal excise tax refund included in other operating income, net.

<sup>(</sup>h) Represents other income from litigation settlement.

### Schedule B

## Turning Point Brands, Inc.

## Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS

(dollars in thousands except share data)

(unaudited)

(unuuneu)		Three Months	Ended	Three Months Ended						
		December 31	, 2023	December 31, 2022						
	Ne	t Income	Dilu	ted EPS	Net Ir	ncome (Loss)	Diluted EPS			
GAAP	\$	10,109	\$	0.53	\$	(16,317)	\$	(0.93)		
Anti-dilutive impact (a)		-		0.00		-		0.20		
Gain on extinguishment of debt (b)		146		0.01		(714)		(0.03)		
Corporate and CDS restructuring (c)		150		0.01		1,473		0.07		
ERP/CRM (d)		104		0.01		271		0.01		
Stock options, restricted stock, and incentives expense (e)		1,434		0.07		944		0.05		
Transactional expenses and strategic initiatives (f)		2		0.00		10		0.00		
FDA PMTA (g)		757		0.04		233		0.01		
Non-cash asset impairment (h)		766		0.04		28,109		1.35		
FET refund (i)		(3,843)		(0.19)		-		-		
Legal settlement (j)		(3,017)		(0.15)		-		-		
Deferred tax valuation allowance (k)		8,383		0.42		-		-		
Impact of quarterly tax items to effective tax rate (l)		311		0.02		(804)		(0.04)		
Adjusted	\$	15,302	\$	0.79	\$	13,205	\$	0.69		

Total may not foot due to rounding

Note: Quarterly tax rate used excludes impact of deferred tax valuation allowance.

<sup>(</sup>a) Represents dilution of options and debt conversion that is anti-dilutive and not included for GAAP.

<sup>(</sup>b) Represents gain on extinguishment of debt tax effected at the quarterly tax rate.

<sup>(</sup>c) Represents costs associated with corporate and CDS restructuring, including severance tax effected at the quarterly tax rate.

<sup>(</sup>d) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the quarterly tax rate.

<sup>(</sup>e) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.

<sup>(</sup>f) Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.

<sup>(</sup>g) Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.

<sup>(</sup>h) Represents impairment of goodwill, intangible and investment assets tax effected at the quarterly tax rate.

<sup>(</sup>i) Represents federal excise tax refund and related interest income effected at the quarterly tax rate.

<sup>(</sup>j) Represents receivable from legal settlement tax effected at the quarterly tax rate.

<sup>(</sup>k) Represents deferred tax valuation allowance.

<sup>(1)</sup> Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2023 and 2022.

#### Schedule B

#### **Turning Point Brands, Inc.**

## Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS

(dollars in thousands except share data)

(unaudited)

(manarea)													
		For the Yea	r Ended		For the Year Ended								
		December 3	31, 2023	December 31, 2022									
	Ne	et Income	Dilu	ted EPS	No	et Income	Diluted EPS						
GAAP	\$	38,462	\$	2.01	\$	11,641	\$	0.64					
Anti-dilutive impact (a)		-		(0.00)		-		0.09					
Gain on extinguishment of debt (b)		(1,245)		(0.06)		(617)		(0.03)					
Corporate and CDS restructuring (c)		291		0.01		2,401		0.11					
ERP/CRM (d)		413		0.02		1,368		0.06					
Stock options, restricted stock, and incentives expense (e)		4,910		0.24		3,676		0.17					
Transactional expenses and strategic initiatives (f)		123		0.01		558		0.03					
FDA PMTA (g)		1,570		0.08		3,174		0.15					
Non-cash asset impairment (h)		9,114		0.45		28,674		1.35					
FET refund (i)		(3,813)		(0.19)		-		-					
Legal settlement (j)		(2,994)		(0.15)		-		-					
Deferred tax valuation allowance (k)		8,383		0.41		-		-					
Impact of annual tax items to effective tax rate (l)		1,587		0.08		5,309		0.25					
Adjusted	\$	56,802	\$	2.91	\$	56,183	\$	2.83					

Total may not foot due to rounding

Note: Annual tax rate used excludes impact of deferred tax valuation allowance.

- (a) Represents dilution of debt conversion that is anti-dilutive and not included for GAAP.
- (b) Represents gain on extinguishment of debt tax effected at the annual tax rate.
- (c) Represents costs associated with corporate and CDS restructuring, including severance tax effected at the annual tax rate.
- (d) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the annual tax rate.
- $(e) \ Represents \ non-cash \ stock \ options, \ restricted \ stock, \ incentives \ expense \ and \ Solace \ PRSUs \ tax \ effected \ at \ the \ annual \ tax \ rate.$
- (f) Represents the fees incurred for transaction expenses tax effected at the annual tax rate.
- (g) Represents costs associated with applications related to the FDA PMTA tax effected at the annual tax rate.
- (h) Represents impairment of goodwill, intangible and investment assets tax effected at the annual tax rate.
- (i) Represents federal excise tax refund and related interest income effected at the annual tax rate.
- (j) Represents receivable from legal settlement tax effected at the annual tax rate.
- (k) Represents deferred tax valuation allowance.
- (l) Represents adjustment from annual tax rate to annual projected tax rate of 23% in 2023 and 2022.

Schedule C

### Turning Point Brands, Inc.

Reconciliation of GAAP Operating Income (Loss) to Adjusted Operating Income (Loss)

(dollars in thousands (unaudited)

(		Consol	idated		Zig-Zag					Stoke		Creative Distribution Solutions																										
	4th	Quarter	4tl	h Quarter	4th	4th Quarter 4th Quarter		4th Quarter		4th Quarter		4th Quarter		4th Quarter																								
		2023		2022		2023	2022		2022		2022		2022		2022		2022		2022		2023		2023		2023		2023		2023		2023		_	2022		2023		2022
Net sales	\$	97,120	\$	103,392	\$	45,092	\$	46,444	\$	37,976	\$	32,010	\$	14,052	\$	24,938																						
Gross profit	\$	50,524	\$	49,563	\$	25,499	\$	25,768	\$	21,883	\$	17,210	\$	3,142	\$	6,585																						
Operating income (loss)	\$	23,953	\$	18,318	\$	20,968	\$	17,362	\$	12,533	\$	12,794	\$	(646)	\$	134																						
Adjustments:																																						
Transactional expenses and strategic initiatives		3		12		-		-		-		-		-		-																						
FDA PMTA		1,003		289		-		-		-		-		-		-																						
Corporate and CDS restructuring		199		1,825		-		-		-		-		-		-																						
ERP/CRM		138		336		-		-		-		-		-		-																						
FET refund		(4,345)		-						(4,345)		-				-																						
Adjusted operating income (loss)	\$	20,951	\$	20,780	\$	20,968	\$	17,362	\$	8,188	\$	12,794	\$	(646)	\$	134																						

Schedule C

Reconciliation of GAAP Operating Income (Loss) to Adjusted Operating Income (Loss)

(dollars in thousands

unaudited)

	Consol	idated		Zig-Zag					Stoker	r's		Creative Distribution Solutions									
	YTD		YTD		YTD	TD YTD			YTD		YTD		YTD YTD		TD	YTD		TD YTD			
	 2023		2022	2023 2022		2023 2022		2022		2022		3 2022		2023		20	022		2023		2022
Net sales	\$ 405,393	\$	415,013	\$	180,455	\$	190,403	\$	144,609	\$ 13	30,826	\$	80,329	\$	93,784						
Gross profit	\$ 203,241	\$	205,538	\$	101,055	\$	106,576	\$	81,887	\$ 7	1,254	\$	20,299	\$	27,708						
Operating income (loss)	\$ 82,577	\$	75,514	\$	68,280	\$	73,342	\$	58,180	\$ 5	3,331	\$	(383)	\$	1,506						
Adjustments:																					
Transactional expenses and strategic initiatives	165		801		-		-		-		-		-		-						
FDA PMTA	2,098		4,554		-		-		-		-		-		-						
Corporate and CDS restructuring	389		3,444		-		-		-		-		190		-						
ERP/CRM	552		1,962		-		-				-		-								
FET refund	(4,345)		-		-		-		(4,345)		-		-		-						
Adjusted operating income (loss)	\$ 81,436	\$	86,275	\$	68,280	\$	73,342	\$	53,835	\$ 5	3,331	\$	(193)	\$	1,506						